Triple-negative breast cancer (TNBC) is a uniquely aggressive cancer with high rates of relapse due to resistance to chemotherapy. TNBC expresses higher levels of programmed cell death-ligand 1 (PD-L1) compared to other breast cancers, providing the rationale for the recently approved immunotherapy with anti-PD-L1 monoclonal antibodies (mAbs). A huge effort is dedicated to identify actionable biomarkers allowing for combination therapies with immune-checkpoint blockade. Platelet-derived growth factor receptor β (PDGFRβ) is highly expressed in invasive TNBC, both on tumor cells and tumor microenvironment. We recently proved that tumor growth and lung metastases are impaired in mouse models of human TNBC by a high efficacious PDGFRβ aptamer. Hence, we aimed at investigating the effectiveness of a novel combination treatment with the PDGFRβ aptamer and anti-PD-L1 mAbs in TNBC.

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer / Camorani, Simona; Passariello, Margherita; Agnello, Lisa; Esposito, Silvia; Collina, Francesca; Cantile, Monica; Di Bonito, Maurizio; Ulasov, Ilya V; Fedele, Monica; Zannetti, Antonella; De Lorenzo, Claudia; Cerchia, Laura. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 39:1(2020), p. 180. [10.1186/s13046-020-01694-9]

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

Passariello, Margherita;Cantile, Monica;Fedele, Monica;Zannetti, Antonella;De Lorenzo, Claudia;Cerchia, Laura
2020

Abstract

Triple-negative breast cancer (TNBC) is a uniquely aggressive cancer with high rates of relapse due to resistance to chemotherapy. TNBC expresses higher levels of programmed cell death-ligand 1 (PD-L1) compared to other breast cancers, providing the rationale for the recently approved immunotherapy with anti-PD-L1 monoclonal antibodies (mAbs). A huge effort is dedicated to identify actionable biomarkers allowing for combination therapies with immune-checkpoint blockade. Platelet-derived growth factor receptor β (PDGFRβ) is highly expressed in invasive TNBC, both on tumor cells and tumor microenvironment. We recently proved that tumor growth and lung metastases are impaired in mouse models of human TNBC by a high efficacious PDGFRβ aptamer. Hence, we aimed at investigating the effectiveness of a novel combination treatment with the PDGFRβ aptamer and anti-PD-L1 mAbs in TNBC.
2020
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer / Camorani, Simona; Passariello, Margherita; Agnello, Lisa; Esposito, Silvia; Collina, Francesca; Cantile, Monica; Di Bonito, Maurizio; Ulasov, Ilya V; Fedele, Monica; Zannetti, Antonella; De Lorenzo, Claudia; Cerchia, Laura. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 39:1(2020), p. 180. [10.1186/s13046-020-01694-9]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/849364
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 35
social impact